SCHEMBL6585634

SCHEMBL6585634

O=S(=O)(N1CCCCC1)n1ccc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.57
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
TSHR P16473 4/20 0.51
HTT P42858 3/20 0.51
ALDH1A1 P00352 2/20 0.51
LMNA P02545 2/20 0.51
HPGD P15428 1/20 0.51
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.46
PKM P14618 1/20 0.46
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MAPT P10636 1/20 0.44
RAPGEF4 Q8WZA2 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MCOLN3 Q8TDD5 2/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29576587 1.00 HTR6 (0.57) HTR6MEN1KMT2ATSHRHTT
SCHEMBL13431733 0.84 HTT (0.57) HTR6MEN1KMT2ATSHRHTT
SCHEMBL8415487 0.82 HTR6 (0.66) HTR6MEN1KMT2ATSHRHTT
SCHEMBL4503543 0.74 HTT (0.44) HTR6MEN1KMT2ATSHRHTT
SCHEMBL10433225 0.72 HTR6 (0.58) HTR6MEN1KMT2ATSHRHTT
SCHEMBL24596834 0.71 HTR6 (0.61) HTR6MEN1KMT2ATSHRHTT
SCHEMBL4065276 0.71 HTR6 (0.61) HTR6MEN1KMT2ATSHRHTT
SCHEMBL649929 0.71 HTR6 (0.61) HTR6MEN1KMT2ATSHRHTT
SCHEMBL5636978 0.71 HTR6 (0.61) HTR6MEN1KMT2ATSHRHTT
SCHEMBL29558089 0.71 HTR6 (0.61) HTR6MEN1KMT2ATSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6777430-B2 A DERIVATIVES WITH ATTACHED TO AN N-ARYLALKYL-SUBSTITUTED AZETIDINE, PYRROLIDINE OR PIPERIDINE RING; A SERATONIN RECEPTOR ANTAGONISTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER SCHIZOPHRENIA, DEPRESSION MERCK SHARP & DOHME LTD. 2004-08-17 US disclosed
EP-1147084-B1 PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2004-05-19 EP disclosed
US-20030203889-A1 Phenylsulphonyl derivatives as 5-HT receptor ligands MERCK & CO., INC. 2003-10-30 US disclosed
US-6559166-B1 A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore MERCK SHARP & DOHME LTD. 2003-05-06 US disclosed
EP-1147084-A1 PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME LTD. (GB) 2001-10-24 EP disclosed
WO-2000043362-A1 PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203889-A1 Phenylsulphonyl derivatives as 5-HT receptor ligands HTR2A, HTR5A, HTR2C HTR6 11/4885MEN1 4821/4885KMT2A 1282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.